Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · JATT II Acquisition Corp. (JATT)

JATT II signs $285 million deal to merge with biotech Talawar Therapeutics

Neutral Impact 5 of 5 m&a Written later

JATT II Acquisition Corp., a blank check company, entered a business combination agreement with Talawar Tx Inc., a biotechnology developer of bispecific antibodies. The combined company is expected to trade on Nasdaq as TLWR and to receive up to $285 million before transaction costs, including a $225 million PIPE financing at $10.00 per share, if there are no redemptions by JATT II shareholders.

Key points

  • Business combination agreement signed June 29, 2026; JATT II shareholders must approve the deal, and closing is expected in the second half of 2026
  • Expected proceeds of $285 million before transaction costs, assuming no redemptions: $60 million from the JATT II trust account plus a $225 million PIPE
  • Combined company expected to trade on Nasdaq Capital Market under ticker TLWR; lead asset TALA-125 targets clinic entry in Q1 2027

The filing

CompanyJATT II Acquisition Corp. (JATT)
Form8-K, current report
Filed with the SECJun 29, 2026, 8:37 AM ET
Accession number0001193125-26-286926

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.